algisyl
Phase 2- Indications
- Heart failure
Company intelligence / Profile preview
The company’s lead product, Algisyl-LVR—a self-gelling biopolymer implanted into the left ventricle—has demonstrated positive one-year results in a randomized international clinical trial for advanced heart failure. It received CE mark approval for use in Europe and has FDA Investigational Device Exemption clearance to begin pivotal trials in the US. Other pipeline assets remain at early/pre-clinical stages.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on LoneStar Heart.